Discover a brand new alliance to serve therapeutic and diagnostic program needs in Discovery, Preclinical, Clinical I/II/III

The development of theranostics requires highly specific expertise and strong collaboration between preclinical and clinical development. Oncodesign and ABX-CRO will present together the prerequisite going into Clinical Phase I and how to evaluate key criteria in preclinical phase.

Register now and take advantage of a 20% discount on your registration thanks to Oncodesign with the code “Onco20”

[Talk] It takes 2 to Tango: Path from Preclinical to Clinical Phase I for Imaging and Therapeutic Radiopharmaceuticals
When? Wednesday 9 December at 1:40pm

Come & listen to Dr. Berthet during his LIVE scientific presentation. He will unveil how Oncodesign-ABX joined expertise and our multi-modal pharmaco-imaging & targeted radiotherapy platforms available to our clients to move their theranostic projects faster.

• Discovery & Preclinical Pharmacology
• Radiolabeling & Pharmaco-Imaging
• Systemic Targeted Radiotherapy
• DMPK, Bioanalysis, Dosimetry
• Toxicology
• Radioactive IND/IMPD development
• Clinical study management I/II/III

Working as a translational team, Oncodesign and ABX-CRO joined know-how from the radiolabeling to late stage development provides optimum research solutions for diagnostic imaging and targeted radiotherapy.

[Panel discussion] Development of theranostics from Preclinical to Clinical Phase I
When? Wednesday 9 December at 2:20pm
[Virtual booth] You can also speak with the team at any time during the conference on Oncodesign/ABX shared virtual booth!

I read the postcard!

Emilie Soulier, Cyril Berthet, Eftychia Koumarianou and Maik Rossmann will be connected to answer all your questions.

I want to know more!